ARCHIVES

Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Joseph Cullen, Cancer Prevention Leader, Dead At 54

November 30, 1990

Fisher, Bonadonna, Croce, Hanafusa Win GAM Cancer Prizes

June 11, 1993

New Jersey Legislature Votes to Oppose USPSTF PSA Screening Downgrade

January 20, 2012

In Brief: NCI’s “Constant Dollar” Budget For FY 1979 Equal To 1975 Amount; Decosse Move to S-K

September 22, 1978

Professional Fundraiser Poses Eight Questions For SU2C 3.

September 19, 2008

Study Recommends Longer Courses Of Chemotherapy For Bone Marrow Cancer

March 31, 2006